Form 4: Nuvation Bio Inc. Executive Granted Stock Options

Gary Hattersley, Chief Scientific Officer of Nuvation Bio Inc., was granted stock options to purchase 500,000 shares of Class A Common Stock.

Summary

• Gary Hattersley, the Chief Scientific Officer of Nuvation Bio Inc., received stock options on February 28, 2025.
• The options grant him the right to purchase 500,000 shares of Class A Common Stock at an exercise price of $1.97 per share.
• The options vest as to 25% on the one-year anniversary of the grant date (February 28, 2025), and then monthly over the subsequent 36 months, contingent upon continuous service.
• The options expire on February 27, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a routine event and suggests confidence in the executive's ability to contribute to the company's success. There are no red flags or negative information in the document.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing him to contribute to the company's success.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in the biotech industry.
• The size of the grant (500,000 shares) and the vesting schedule (25% after one year, then monthly over 36 months) are fairly typical for a Chief Scientific Officer at a company like Nuvation Bio.
• Comparable companies such as Relay Therapeutics, Black Diamond Therapeutics, and Revolution Medicines also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the option grant positively as it incentivizes the CSO to drive company value.
• Employees may see this as a positive sign of investment in leadership.

Key Dates